Publication

A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948).

Smyth, E
; 
Rowley, S
; 
Allum, W
; 
Stenning, S
; 
Wotherspoon, A
; 
Robb, C
; 
Grabsch, H
; 
Alderson, D
; 
Crosby, T
; 
Mason, R
... show 10 more
Citations
Altmetric:
Abstract
Authors
Smyth, E
Rowley, S
Allum, W
Stenning, S
Wotherspoon, A
Robb, C
Grabsch, H
Alderson, D
Crosby, T
Mason, R
Griffin, M
Mansoor, Was
Darby, S
Seymour, M
Thompson, J
Sothi, S
Sumpter, K
Blazeby, J
Langley, R
Cunningham, D
Affiliation
Description
Date
2016-10-01
Publisher
Department of Oncology, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948). 2016, 27(suppl_6):LBA26 Annals of Oncology
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/620277
Embedded videos